CN108367073A - 以双重靶向cd47和egfr来治疗癌症 - Google Patents

以双重靶向cd47和egfr来治疗癌症 Download PDF

Info

Publication number
CN108367073A
CN108367073A CN201680072080.9A CN201680072080A CN108367073A CN 108367073 A CN108367073 A CN 108367073A CN 201680072080 A CN201680072080 A CN 201680072080A CN 108367073 A CN108367073 A CN 108367073A
Authority
CN
China
Prior art keywords
egfr
antibody
cancer
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680072080.9A
Other languages
English (en)
Chinese (zh)
Inventor
欧文·L·唔斯曼
凯利·玛丽·麦肯纳
斯蒂芬·威林汉
桃瑞丝·波河·伊·胡
皮耶罗·D·搭勒吧
延斯-皮特·福尔克默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN202210862489.8A priority Critical patent/CN115569192A/zh
Publication of CN108367073A publication Critical patent/CN108367073A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Zoology (AREA)
CN201680072080.9A 2015-12-11 2016-12-08 以双重靶向cd47和egfr来治疗癌症 Pending CN108367073A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210862489.8A CN115569192A (zh) 2015-12-11 2016-12-08 以双重靶向cd47和egfr来治疗癌症

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562266470P 2015-12-11 2015-12-11
US62/266,470 2015-12-11
US201662380177P 2016-08-26 2016-08-26
US62/380,177 2016-08-26
PCT/US2016/065641 WO2017100462A2 (en) 2015-12-11 2016-12-08 Treatment of cancer with dual targeting of cd47 and egfr

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210862489.8A Division CN115569192A (zh) 2015-12-11 2016-12-08 以双重靶向cd47和egfr来治疗癌症

Publications (1)

Publication Number Publication Date
CN108367073A true CN108367073A (zh) 2018-08-03

Family

ID=59013321

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680072080.9A Pending CN108367073A (zh) 2015-12-11 2016-12-08 以双重靶向cd47和egfr来治疗癌症
CN202210862489.8A Pending CN115569192A (zh) 2015-12-11 2016-12-08 以双重靶向cd47和egfr来治疗癌症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210862489.8A Pending CN115569192A (zh) 2015-12-11 2016-12-08 以双重靶向cd47和egfr来治疗癌症

Country Status (8)

Country Link
US (3) US10344094B2 (enExample)
EP (1) EP3386545A4 (enExample)
JP (2) JP7077226B2 (enExample)
KR (2) KR20250004896A (enExample)
CN (2) CN108367073A (enExample)
AU (3) AU2016365829B2 (enExample)
CA (1) CA3005911A1 (enExample)
WO (1) WO2017100462A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568383B2 (en) * 2015-01-16 2020-02-25 Nike, Inc. Sole system for an article of footwear incorporating a knitted component with a one-piece knit outsole and a tensile element
US9848673B2 (en) 2015-01-16 2017-12-26 Nike, Inc. Vacuum formed knit sole system for an article of footwear incorporating a knitted component
JP7198083B2 (ja) * 2015-08-26 2022-12-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
CN108367073A (zh) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
EA038880B1 (ru) 2016-01-11 2021-11-01 Форти Севен, Инк. Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
KR102776457B1 (ko) * 2017-10-18 2025-03-06 포티 세븐, 엘엘씨 항-cd47 작용제-기초된 난소암 요법
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
ES2927305T3 (es) 2018-02-12 2022-11-04 Forty Seven Inc Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
US20210040219A1 (en) * 2018-03-13 2021-02-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by egfr antibody
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
WO2021046216A1 (en) * 2019-09-03 2021-03-11 Arch Oncology, Inc. Methods for identifying biomarkers to predict treatment response
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328505A (zh) * 2010-10-29 2013-09-25 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN106519036A (zh) * 2016-11-04 2017-03-22 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用
CN107459579A (zh) * 2016-06-01 2017-12-12 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US20130236449A1 (en) * 2010-04-21 2013-09-12 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
HRP20170254T1 (hr) 2010-05-14 2017-04-21 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
WO2014179132A1 (en) * 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US20160036232A1 (en) 2015-10-09 2016-02-04 LT Lighting (Taiwan) Corp. Maximum energy utilization point tracking technologies
CN108367073A (zh) 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328505A (zh) * 2010-10-29 2013-09-25 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN107459579A (zh) * 2016-06-01 2017-12-12 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
CN106519036A (zh) * 2016-11-04 2017-03-22 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JIE LIU等: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", 《PLOS ONE》 *
JIE LIU等: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", 《PLOS ONE》, vol. 10, no. 9, 21 September 2015 (2015-09-21), XP055223677, DOI: 10.1371/journal.pone.0137345 *
JOOST P J J HEGMANS、JOACHIM G J V AERTS: "Immunomodulation in cancer", 《CURR OPIN PHARMACOL》, 8 July 2014 (2014-07-08), pages 17 - 21 *
KIPP WEISKOPF等: "Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies", 《SCIENCE》 *
KIPP WEISKOPF等: "Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies", 《SCIENCE》, vol. 341, no. 6141, 5 July 2013 (2013-07-05), pages 88 - 91, XP093026969, DOI: 10.1126/science.1238856 *
窦肇华等: "《免疫细胞学与疾病》", 30 September 2004, 中国医药科技出版社, pages: 262 - 265 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用

Also Published As

Publication number Publication date
AU2023201938A1 (en) 2023-05-04
US20190322751A1 (en) 2019-10-24
US11130813B2 (en) 2021-09-28
CA3005911A1 (en) 2017-06-15
AU2023201938B2 (en) 2025-11-20
KR20180083895A (ko) 2018-07-23
AU2016365829B2 (en) 2020-02-06
US20170166645A1 (en) 2017-06-15
JP7077226B2 (ja) 2022-05-30
KR102763202B1 (ko) 2025-02-07
CN115569192A (zh) 2023-01-06
JP7494245B2 (ja) 2024-06-03
AU2016365829A1 (en) 2018-06-07
KR20250004896A (ko) 2025-01-08
AU2020202712B2 (en) 2023-01-05
US20220033506A1 (en) 2022-02-03
EP3386545A2 (en) 2018-10-17
JP2022116095A (ja) 2022-08-09
JP2019505485A (ja) 2019-02-28
US12037402B2 (en) 2024-07-16
AU2020202712A1 (en) 2020-05-14
US10344094B2 (en) 2019-07-09
WO2017100462A2 (en) 2017-06-15
EP3386545A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
JP7494245B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
KR102418979B1 (ko) Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
JP7026047B2 (ja) 免疫調節剤を併用するがんの治療
JP2020522691A (ja) Ｌａｇ−３陽性腫瘍の処置
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
JP2021500349A (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
KR20200070341A (ko) 항-cd47 및 항-pd-l1로 난소암의 치료
HK40084229A (en) Treatment of cancer with dual targeting of cd47 and egfr
HK1259512A1 (en) Treatment of cancer with dual targeting of cd47 and egfr
JP2023549581A (ja) ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法
EA045764B1 (ru) Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259512

Country of ref document: HK